MedTrace Logo

An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications

NCT04322188 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2020-06-01

No results posted yet for this study

Summary

This observational study will collect data from patients treated with siltuximab program for treatment of SARS-CoV-2 infection complicated with serious respiratory complications.

This observational study will group the patients into two cohorts receiving siltuximab..

Outcome of patients will be compared to a cohort of patients receiving standard treatment without siltuximab.

The patients will be divided into 2 cohorts. Those contained in Cohort A were treated after the use of continuous positive airways pressure (CPAP) or non-invasive ventilation (NIV). Patients in Cohort B were treated after intubation

Conditions

  • Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection

Interventions

OTHER

this is an observational study. No intervention is applicable; patients are managed as per clinicians' best judgement and best practice

Sponsors & Collaborators

  • A.O. Ospedale Papa Giovanni XXIII

    lead OTHER

Principal Investigators

  • Giuseppe GRITTI, MD · ASST PAPA GIOVANNI XXIII

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-19
Primary Completion
2020-05-08
Completion
2020-05-08

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04322188 on ClinicalTrials.gov